VIDEO: Novel tyrosine kinase 2 inhibitor ‘potentially’ effective in psoriasis treatment

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on TAK-279, a tyrosine kinase 2 inhibitor, in the treatment of individuals with severe psoriasis.

In the study, 259 patients were randomly assigned to 2 mg, 5 mg, 15 mg or 30 mg of once-daily TAK-279 or placebo for 12 weeks. Of the individuals receiving the study drug, 68% of the 15 mg group and 67% of the 30 mg group reached the primary endpoint of PASI 75. This was in comparison to 6% of the placebo group.

Also, 53% to 62% of subjects in the treatment groups and 44% of those in the placebo group experienced adverse events.

“Overall, this does seem to be a very effective oral agent potentially, so I’ll be interested to see how it looks when it comes out to phase 3 data, which hopefully will come out in a few years,” Wu, a voluntary associate professor in the department of dermatology at University of Miami Miller School of Medicine, said.

Reference:

• Armstrong AW. Efficacy and safety results from the randomized, double-blind, placebo-controlled phase 2b trial of TYK2 inhibitor NDI-034858 in moderate to severe psoriasis. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans.